Ohr Pharmaceutical, Inc. (OHRP) financial statements (2021 and earlier)

Company profile

Business Address 700 TECHNOLOGY DRIVE
PITTSBURGH, PA 15219
State of Incorp. DE
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
TTM
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2832104131329
Cash and cash equivalents2832104131329
Prepaid expense1100010
Other undisclosed current assets000 0  
Total current assets:2933114131329
Noncurrent Assets
Property, plant and equipment1100000
Long-term investments and receivables001    
Long-term investments001    
Intangible assets, net (including goodwill)  08151617
Goodwill    111
Intangible assets, net (excluding goodwill)  08141516
Prepaid expense000    
Other undisclosed noncurrent assets0   000
Total noncurrent assets:2228151617
TOTAL ASSETS:31341312282946
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2221542
Accounts payable121    
Accrued liabilities110    
Other undisclosed accounts payable and accrued liabilities   1542
Debt 000000
Other liabilities010    
Other undisclosed current liabilities      2
Total current liabilities:2331544
Noncurrent Liabilities
Liabilities, other than long-term debt    0  
Deferred compensation liability, classified    0  
Total noncurrent liabilities:    0  
Total liabilities:2331544
Stockholders' equity
Stockholders' equity attributable to parent29311011232542
Common stock0000000
Additional paid in capital767537132131109101
Accumulated deficit(48)(44)(27)(121)(108)(84)(59)
Total stockholders' equity:29311011232542
TOTAL LIABILITIES AND EQUITY:31341312282946

Income statement (P&L) ($ in millions)

12/31/2020
TTM
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
Gross profit:00 0 0 
Operating expenses(18)(17)(26)(10)(24)(25)(18)
Other undisclosed operating income (loss)(0)(0) (4)010
Operating loss:(18)(17)(26)(14)(24)(25)(18)
Nonoperating income (expense)1(0) 1(0)(1)3
Other nonoperating income (expense)1(0) 1(0) 0
Interest and debt expense(0)(0)(0)1 1(0)
Loss from continuing operations before equity method investments, income taxes:(17)(17)(26)(12)(24)(25)(15)
Loss from equity method investments      (0)
Other undisclosed income (loss) from continuing operations before income taxes     (1)0
Net loss:(17)(17)(26)(12)(24)(26)(15)
Other undisclosed net income (loss) attributable to parent00(0)(1)   
Net loss available to common stockholders, diluted:(17)(17)(27)(13)(24)(26)(15)

Comprehensive Income ($ in millions)

12/31/2020
TTM
9/30/2020
9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
Net loss:(17)(17)(26)(12)(24)(26)(15)
Comprehensive loss, net of tax, attributable to parent:(17)(17)(26)(12)(24)(26)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: